Companies / Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Nasdaq: LXRXCIK 1062822THE WOODLANDS, TXlexpharma.com ↗

Financials · FY2025

Revenue$49.80M
Net income$-50.34M
Total debt$51.44M
Cash$40.92M
Diluted EPS$-0.14
Shares outstanding445.0M

Ownership

445.0M shares outstanding · as of Aug 3, 2026
40.8%Insiders
Ownership
Insiders40.83%181,670,606
Institutions67.81%301,707,227
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 26

View all →
Insider% of sharesShares
Artal Participations S.a r.l.Director · 10% owner
39.36%175,156,062
Debbane RaymondDirector
0.45%1,995,498
Invus, L.P.Director · 10% owner
0.35%1,538,462
Crum Brian TSVP, General Counsel & Secr.
0.10%428,802
Amouyal PhilippeDirector
0.08%374,486
Granowitz Craig BSVP, Chief Medical Officer
0.07%323,430
Exton MichaelCEOChief Executive Officer · Director
0.07%298,432
Sobecki Christopher JDirector
0.07%293,177
McDermott WendySVP, Human Resources
0.06%277,945
Barker Sam LDirector
0.05%213,771

Institutional holders 133

View all →
HolderValue% of shares
Artal Group S.A.$241.39M34.78%
Siren, L.L.C.$44.76M8.75%
Fmr LLC$43.51M8.50%
BlackRock, Inc.$41.64M3.90%
State Street Corporation$11.80M1.11%
Vanguard Group Inc$11.05M2.16%
Millennium Management LLC$7.71M1.11%
Geode Capital Management, LLC$4.95M0.71%
Marshall Wace, LLP$3.71M0.53%
UBS Group AG$3.46M0.68%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 2, 2026Invus, L.P.
Director
GrantCommon Stock$24.12M+18.6M
+13.62%
154,734,327
34.78% of shares
low
Feb 2, 2026Invus, L.P.
Director
GrantSeries B Convertible Preferred Stock$23.86M+367K
367,145
0.08% of shares
low
Feb 2, 2026Invus, L.P.
Director
GrantCommon Stock$5.00M+3.8M
+109.38%
7,362,368
1.65% of shares
low
Feb 17, 2026Artal Participations S.a r.l.
Director
GrantSeries B Convertible Preferred Stock$2.68M+41K
+11.25%
408,435
0.09% of shares
low
Feb 2, 2026Invus, L.P.
Director
BuyCommon Stock$2.00M+1.5M
1,538,462
0.35% of shares
high
Feb 28, 2026Exton Michael
CEO
OtherCommon Stock$301.1K-205K
-40.70%
298,432
0.07% of shares
low
Feb 18, 2026Debbane Raymond
Director
BuyCommon Stock$176.5K+134K
+8.79%
1,654,186
0.37% of shares
medium
Feb 28, 2026Granowitz Craig B
Executive
OtherCommon Stock$160.4K-109K
-25.22%
323,430
0.07% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
LXRXCommon StockEquity528872302BBG000BQ85G2